Clinical Trials Logo

Brugada Syndrome clinical trials

View clinical trials related to Brugada Syndrome.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04504591 Terminated - Brugada Syndrome 1S Clinical Trials

Validation Of A New S-ICD Algorithm To Reduce Oversensing Of Dynamic T-Waves In Patients With Brugada Syndrome

DE-08-16
Start date: December 14, 2017
Phase:
Study type: Observational

The main objective of this study will be to assess the efficacy of S-ICD with SMART Pass to discriminate dynamic T-waves amplitudes and morphologies over time. Pilot, multi-centric, prospective, blinded, one arm (repeated measures), non-interventional study. Objective is to setup a 8-center data collection registry between Switzerland, Italy and Belgium.

NCT ID: NCT00927732 Terminated - Brugada Syndrome Clinical Trials

Hydroquinidine Versus Placebo in Patients With Brugada Syndrome

Quidam
Start date: February 2009
Phase: Phase 3
Study type: Interventional

The specific aim of this study is to determine whether hydroquinidine administration can prevent heart from appearance of ventricular arrhythmia detected by the automatic implantable defibrillator (ICD).

NCT ID: NCT00701077 Terminated - Brugada Syndrome Clinical Trials

DAPERB 3,4-DiAminoPyridine and Electrophysiological Response in Brugada Syndrome

DAPREB
Start date: September 12, 2008
Phase: Phase 3
Study type: Interventional

The Brugada syndrome is a rare disease potentially leading to severe arrhythmic events in otherwise healthy subjects.In many patients an Implantable cardiovertor defibrillator (ICD) is implanted to prevent sudden cardiac death. ICD are however associated with potential complications and are not available in all countries.Pharmacological blockade of specific ion channels (Ito) represents a promising therapeutic approach in this syndrome.The 3,4-diaminopyridine (3,4-DAP) is a pharmacological Ito blocker that can be used in humans.The aim of the study is to evaluate the effect of 3,4-DAP on ventricular arrhythmia inducibility in Brugada patients requiring an electrophysiological study for arrhythmic risk stratification.